Erratum: Hepatitis E virus ORF3 is a functional ion channel required for release of infectious particles (Proceedings of the National Academy of Sciences of the United States of America (2017) 114 (1147-1152) DOI: 10.1073/pnas.1614955114);Hepatitis e virus ORF3 is a functional ion channel required for release of infectious particles

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 5, 2017, Pages 1147-1152

  Ding, Qiang ^a   Heller, Brigitte ^a   Capuccino, Juan M V ^b   Song, Bokai ^a   Nimgaonkar, Ila ^a   Hrebikova, Gabriela ^a   Contreras, Jorge E ^b   Ploss, Alexander ^a  

^a PRINCETON UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Drug development; Hepatitis E; Hepatitis E virus; Virion release; Viroporin

Indexed keywords

ION CHANNEL; ORF3 ION CHANNEL; PROTEIN M2; UNCLASSIFIED DRUG; HYBRID PROTEIN; M1 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; ORF3 PROTEIN, HEPATITIS E VIRUS; VIRAL PROTEIN;

CARBOXY TERMINAL SEQUENCE; CELL LYSATE; CELLULAR DISTRIBUTION; CONFERENCE PAPER; EMBRYO; ENDOPLASMIC RETICULUM; HEK293 CELL LINE; HEP-G2 CELL LINE; HEPATITIS E; HEPATITIS E VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLUENZA A VIRUS; ION CURRENT; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REVERSAL POTENTIAL; VIRUS RELEASE; VIRUS TRANSMISSION; VOLTAGE CLAMP TECHNIQUE; WESTERN BLOTTING; XENOPUS LAEVIS; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL; CHEMISTRY; GENE DELETION; GENETICS; ION TRANSPORT; METABOLISM; PATCH CLAMP TECHNIQUE; PHYSIOLOGY; PROTEIN DOMAIN; PROTEIN MOTIF; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ENDOPLASMIC RETICULUM; GENE DELETION; HEK293 CELLS; HEP G2 CELLS; HEPATITIS E VIRUS; HUMANS; ION CHANNELS; ION TRANSPORT; OOCYTES; PATCH-CLAMP TECHNIQUES; PROTEIN DOMAINS; RECOMBINANT FUSION PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL MATRIX PROTEINS; VIRAL PROTEINS; VIRUS RELEASE; VIRUS REPLICATION; XENOPUS LAEVIS;

EID: 85011303864     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1708260114     Document Type: Erratum

References (45)

1. Dalton HR, Bendall R, Ijaz S, Banks M (2008) Hepatitis E: An emerging infection in developed countries. Lancet Infect Dis 8(11):698-709.
2. Kamar N, et al. (2008) Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 358(8):811-817.
3. Schildgen O, Müller A, Simon A (2008) Chronic hepatitis E and organ transplants. N Engl J Med 358(23):2521-2522, author reply 2522.
4. Dalton HR, Bendall RP, Keane FE, Tedder RS, Ijaz S (2009) Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med 361(10):1025-1027.
5. Colson P, Kaba M, Moreau J, Brouqui P (2009) Hepatitis E in an HIV-infected patient. J Clin Virol 45(4):269-271.
6. Colson P, Dhiver C, Gerolami R (2008) Hepatitis E virus as a newly identified cause of acute viral hepatitis during human immunodeficiency virus infection. Clin Microbiol Infect 14(12):1176-1180.
7. Zhang J, et al. (2015) Long-term efficacy of a hepatitis E vaccine. N Engl J Med 372(10): 914-922.
8. Mallet V, et al. (2010) Brief communication: Case reports of ribavirin treatment for chronic hepatitis E. Ann Intern Med 153(2):85-89.
9. Kamar N, et al. (2010) Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection. Gastroenterology 139(5):1612-1618.
10. Debing Y, et al. (2016) Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity. J Hepatol 65(3):499-508.
11. Cao D, Meng XJ (2012) Molecular biology and replication of hepatitis E virus. Emerg Microbes Infect 1(8):e17.
12. Ahmad I, Holla RP, Jameel S (2011) Molecular virology of hepatitis E virus. Virus Res 161(1):47-58.
13. Takahashi M, et al. (2008) Monoclonal antibodies raised against the ORF3 protein of hepatitis E virus (HEV) can capture HEV particles in culture supernatant and serum but not those in feces. Arch Virol 153(9):1703-1713.
14. Emerson SU, et al. (2010) Release of genotype 1 hepatitis E virus from cultured hepatoma and polarized intestinal cells depends on open reading frame 3 protein and requires an intact PXXP motif. J Virol 84(18):9059-9069.
15. Nagashima S, et al. (2011) A PSAP motif in the ORF3 protein of hepatitis E virus is necessary for virion release from infected cells. J Gen Virol 92(Pt 2):269-278.
16. Yamada K, et al. (2009) ORF3 protein of hepatitis E virus is essential for virion release from infected cells. J Gen Virol 90(Pt 8):1880-1891.
17. Shukla P, et al. (2011) Cross-species infections of cultured cells by hepatitis E virus and discovery of an infectious virus-host recombinant. Proc Natl Acad Sci USA 108(6):2438-2443.
18. Kenney SP, Wentworth JL, Heffron CL, Meng XJ (2015) Replacement of the hepatitis E virus ORF3 protein PxxP motif with heterologous late domain motifs affects virus release via interaction with TSG101. Virology 486:198-208.
19. Ishikawa H, Barber GN (2008) STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455(7213):674-678.
20. Tyagi S, Surjit M, Roy AK, Jameel S, Lal SK (2004) The ORF3 protein of hepatitis E virus interacts with liver-specific alpha1-microglobulin and its precursor alpha1-microglobulin/ bikunin precursor (AMBP) and expedites their export from the hepatocyte. J Biol Chem 279(28):29308-29319.
21. Pinto LH, Holsinger LJ, Lamb RA (1992) Influenza virus M2 protein has ion channel activity. Cell 69(3):517-528.
22. Cordes FS, Tustian AD, Sansom MS, Watts A, Fischer WB (2002) Bundles consisting of extended transmembrane segments of Vpu from HIV-1: Computer simulations and conductance measurements. Biochemistry 41(23):7359-7365.
23. Li F, et al. (2014) Efficient genetic manipulation of the NOD-Rag1-/-IL2RgammaC-null mouse by combining in vitro fertilization and CRISPR/Cas9 technology. Sci Rep 4:5290.
24. Zafrullah M, Ozdener MH, Panda SK, Jameel S (1997) The ORF3 protein of hepatitis E virus is a phosphoprotein that associates with the cytoskeleton. J Virol 71(12):9045-9053.
25. Emerson SU, Nguyen H, Torian U, Purcell RH (2006) ORF3 protein of hepatitis E virus is not required for replication, virion assembly, or infection of hepatoma cells in vitro. J Virol 80(21):10457-10464.
26. Holsinger LJ, Nichani D, Pinto LH, Lamb RA (1994) Influenza A virus M2 ion channel protein: A structure-function analysis. J Virol 68(3):1551-1563.
27. Kenney SP, et al. (2012) The PSAP motif within the ORF3 protein of an avian strain of the hepatitis E virus is not critical for viral infectivity in vivo but plays a role in virus release. J Virol 86(10):5637-5646.
28. Surjit M, Oberoi R, Kumar R, Lal SK (2006) Enhanced alpha1 microglobulin secretion from hepatitis E virus ORF3-expressing human hepatoma cells is mediated by the tumor susceptibility gene 101. J Biol Chem 281(12):8135-8142.
29. Sze CW, Tan YJ (2015) Viral membrane channels: Role and function in the virus life cycle. Viruses 7(6):3261-3284.
30. Nieva JL, Madan V, Carrasco L (2012) Viroporins: Structure and biological functions. Nat Rev Microbiol 10(8):563-574.
31. Terwilliger EF, Cohen EA, Lu YC, Sodroski JG, Haseltine WA (1989) Functional role of human immunodeficiency virus type 1 vpu. Proc Natl Acad Sci USA 86(13):5163-5167.
32. Iwatsuki-Horimoto K, et al. (2006) The cytoplasmic tail of the influenza A virus M2 protein plays a role in viral assembly. J Virol 80(11):5233-5240.
33. Lu W, et al. (2006) Severe acute respiratory syndrome-associated coronavirus 3a protein forms an ion channel and modulates virus release. Proc Natl Acad Sci USA 103(33):12540-12545.
34. Jones CT, Murray CL, Eastman DK, Tassello J, Rice CM (2007) Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J Virol 81(16):8374-8383.
35. Steinmann E, et al. (2007) Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog 3(7):e103.
36. Suzuki T, et al. (2010) The human polyoma JC virus agnoprotein acts as a viroporin. PLoS Pathog 6(3):e1000801.
37. Yin X, Ambardekar C, Lu Y, Feng Z (2016) Distinct entry mechanisms for nonenveloped and quasi-enveloped hepatitis E viruses. J Virol 90(8):4232-4242.
38. Feng Z, et al. (2013) A pathogenic picornavirus acquires an envelope by hijacking cellular membranes. Nature 496(7445):367-371.
39. Yin X, Li X, Feng Z (2016) Role of envelopment in the HEV life cycle. Viruses 8(8):E229.
40. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH (1985) The molecular basis of the specific anti-influenza action of amantadine. EMBO J 4(11):3021-3024.
41. Pavlovic D, et al. (2003) The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proc Natl Acad Sci USA 100(10): 6104-6108.
42. Steinmann E, et al. (2007) Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. Hepatology 46(2):330-338.
43. Foster TL, et al. (2011) Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus p7 ion channel. Hepatology 54(1):79-90.
44. Ewart GD, Mills K, Cox GB, Gage PW (2002) Amiloride derivatives block ion channel activity and enhancement of virus-like particle budding caused by HIV-1 protein Vpu. Eur Biophys J 31(1):26-35.
45. Wilson L, Gage P, Ewart G (2006) Hexamethylene amiloride blocks E protein ion channels and inhibits coronavirus replication. Virology 353(2):294-306.